US FDA’s Preferred Special Treatment For Cannabinoids Points To Mistreating Industry

Senate bill provision allowing FDA to develop unique labeling and packaging for cannabinoid supplements and foods is unnecessary, as the products should following existing labeling regulations, says CRN chief Steve Mister.

The more the US Food and Drug Administration treats cannabinoids different from other dietary ingredients, says Council for Responsible Nutrition president and CEO Steve Mister, the more likely are changes to the regulatory framework that would harm the dietary supplement industry.

The latest exception that the FDA’s approach for making lawful the use cannabinoids, with cannabidiol (CBD) the most common in products other than drugs that the CRN sees as unnecessary and unhelpful is a provision in a recently introduced Senate bill, S

More from Cannabis/CBD

More from Ingredients & Safety